非诺贝特联合二甲双胍治疗 2 型糖尿病的疗效分析

Effect of Enofibrate combined with Metformin on type 2 diabetes mellitus

摘要:

目的 探讨非诺贝特联合二甲双胍治疗2 型糖尿病（T2DM）的疗效。方法 选取2014 年6 月- 2016 年6 月沧州市中心医院治疗的112 例T2DM 患者，按随机数字表法将其分为对照组和研究组，每组56 例。 对照组予以二甲双胍治疗，口服二甲双胍0.5 g，2 次/d ；研究组基于对照组结合非诺贝特治疗，口服非诺贝 特0.2 g，1 次/d。两组均持续用药3 个月。观察并比较两组临床疗效、治疗后血清Nesfatin-1、视黄醇结合 蛋白4（RBP4）、脂联素（APN）水平及安全性。结果 研究组总有效率高于对照组（87.50% vs 69.64%）（P <0.05）； 研究组治疗后血清Nesfatin-1、APN 水平高于对照组，而RBP4 低于对照组（P <0.05）；两组不良反应情况 比较，差异无统计学意义（P >0.05）。结论 非诺贝特联合二甲双胍治疗T2DM 能有效改善血糖，其机制可能 与有效控制血清Nesfatin-1、RBP4 及APN 水平有关。

Abstract:

Objective To explore the effect of Enofibrate combined with Metformin on type 2 diabetes mellitus. Methods A total of 112 cases of Type 2 diabetes from June 2014 to June 2016 were divided into control group (56 cases) and research group (56 cases) according to the table of random number. The control group was treated with Metformin (0.5 g Bid), the research group was based on control group combined with Eenofibrate (2 g Qd), both groups were treated for 3 months. Clinical outcomes, levels of serum Nesfatin-1, retinol binding protein-4 (RBP4) and adiponectin (APN) and safety were observed and compared between the groups. Results Total effective rate of the research group was (87.50%) higher than the control group (69.64%), the difference was statistically significant (P < 0.05). After treatment, levels of Nesfatin-1 and serum APN in research group were higher than the control group, while level of RBP4 was lower in research group than the control group, the difference was statistically significant (P < 0.05). The adverse reaction of the two groups was not different (P > 0.05). Conclusions Fenofibrate combined with Metformin in patients with type 2 diabetes can effectively improve blood glucose and control serum levels of Nesfatin-1, RBP4 and APN.